Newsfeeds - Spark Newswire

1 minute read

Why Are Investors Cheering Cardiff Oncology’s New Data In Colorectal Cancer Setting?

Today, 5:41 AM

Cardiff Oncology Inc (NASDAQ:CRDF) has announced new data from Phase 1b/2 evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line…

CRDF

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 5:41 AM

Gainers

BYSI

5 minute read

Cardiff Oncology Announces New Data From Phase 1b/2 Trial In KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate And Progression Free Survival

By Bill Haddad

Today, 5:41 AM

8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evaluable for disease response as of the data cut-off achieved a partial response (PR).

CRDF

5 minute read

The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod

By Shanthi Rexaline

Today, 5:41 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7)

ADIL

3 minute read

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week

By Shanthi Rexaline

Today, 5:41 AM

Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday weekend.

AFMD

1 minute read

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $26

By Benzinga Newsdesk

Today, 5:41 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $25 to $26.

CRDF

6 minute read

84 Biggest Movers From Friday

By Lisa Levin

Today, 5:41 AM

Gainers

ACOR

1 minute read

Cardiff Oncology Q2 EPS $(0.17) Up From $(0.51) YoY

By Bill Haddad

Today, 5:41 AM

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share. This is a 66.67 percent increase over losses of $(0.51) per share from the same period last year.

CRDF

4 minute read

Cardiff Oncology Names Katherine Katherine As Chief Medical Officer, Names James E. Levine As CFO

By Benzinga Newsdesk

Today, 5:41 AM

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal

CRDF